NRG-GY018 — Pembrolizumab added to paclitaxel and carboplatin in advanced or recurrent endometrial cancer

Phase 3 · Endometrial Cancer

Population

Measurable stage III–IV or recurrent endometrial cancer.

Primary Endpoint

Progression-free survival

Rationale

Chemotherapy alone gives short-lived disease control in advanced endometrial cancer. NRG-GY018 tests adding pembrolizumab to standard chemotherapy in both mismatch-repair-deficient and -proficient tumors to define who benefits from first-line immunotherapy.

What It Could Change

Helped establish chemo-immunotherapy as a first-line standard in endometrial cancer; ongoing follow-up defines the long-term survival benefit.